保留Retzius间隙机器人辅助前列腺癌根治术:尿功能与生活质量持久改善且不影响肿瘤学疗效
单术者系列比较70例标准机器人辅助前列腺癌根治术(S-RARP)与随后70例保留Retzius间隙入路(RS-RARP)的围手术期、功能与肿瘤学结局。RS-RARP总体控尿率(95.7% vs 85.7%,p=0.042)和12个月控尿率(97.6% vs 81.4%,p=0.002)更优,恢复控尿更快(44 vs 131天,p<0.001),EPIC-CP尿失禁与总体生活质量评分至12个月持续更佳,切缘阳性率与生化复发无差异。
要点
- RS-RARP较S-RARP显著提高总体及12个月控尿率并加快控尿恢复。
- RS-RARP的EPIC-CP尿失禁与总体生活质量评分在12个月时仍更优。
- 总体切缘阳性率与生化复发无差异,非局灶切缘阳性率更低。
核心结论
- RS-RARP显著改善早期与长期控尿且不损害肿瘤学结局,并带来总体生活质量改善。
- 多因素分析中RS-RARP与12个月EPIC-CP尿失禁改善及生活质量评分改善显著相关,但与切缘阳性或生化复发无关。
研究设计与样本
- 单术者系列,先连续完成70例S-RARP,随后完成70例RS-RARP,共140例。
- 术前及随访至12个月比较人口学、病理与功能结局,功能结局采用EPIC-CP评估。
- 采用logistic与线性回归分析EPIC-CP尿失禁及总体生活质量相关变量,Cox回归分析12个月尿失禁。
主要发现
- 中位随访时间S-RARP为46.3个月,RS-RARP为12.3个月。
- 总体控尿率RS-RARP为95.7%、S-RARP为85.7%(p=0.042);12个月控尿率分别为97.6%与81.4%(p=0.002)。
- 恢复控尿(零至一片安全垫)时间RS-RARP为44天、S-RARP为131天(p<0.001)。
- RS-RARP的EPIC-CP尿失禁与总体生活质量评分在12个月时仍显著更优。
- 总体切缘阳性率无差异,RS-RARP非局灶切缘阳性率更低;性功能无差异。
关键数值与推荐
- 控尿定义为零片垫或零至一片安全垫。
- 主要测量指标包括切缘阳性、生化复发、总体及12个月控尿率、控尿时间、勃起功能、EPIC-CP尿失禁、性功能与总体生活质量评分。
临床怎么用
- 在合适患者中可考虑RS-RARP以加快控尿恢复并改善12个月尿功能与生活质量。
- 选择术式时不应以肿瘤学控制为代价,本系列显示切缘阳性与生化复发无差异。
- 需结合术者学习曲线与病例选择评估该技术的可行性与可推广性。
局限性
- 回顾性研究设计。
- 两组随访时间不相等,RS-RARP随访较短。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Retzius-sparing robot-assisted radical prostatectomy (RS-RARP) has been shown to improve continence. However, questions remain regarding feasibility and generalizability of technique and outcomes. OBJECTIVE: To compare the outcomes of 140 consecutive standard robot-assisted radical prostatectomy (S-RARP) versus RS-RARP. DESIGN, SETTING, AND PARTICIPANTS: A total of 70 S-RARPs were performed followed by 70 RS-RARPs. Demographic, pathologic, and functional outcomes were compared preoperatively and through 12 mo. Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) was used to compare functional outcomes. Logistic and linear regression analyses were utilized to analyze variables associated with EPIC-CP urinary incontinence and overall quality of life (QOL) scores, and oncologic outcomes. Cox regression analysis was used to analyze incontinence at 12 mo. SURGICAL PROCEDURE: RS-RARP versus S-RARP. MEASUREMENTS: Patient and tumor characteristics (age, body mass index, prostate-specific antigen, Charlson Comorbidity Index, Gleason group, clinical stage, and Prostate Imaging Reporting and Data System score), perioperative outcomes (console time, estimated blood loss, postoperative complications, and length of stay), oncologic outcomes (positive surgical margin [PSM], and biochemical recurrence), overall and 12-mo continence rates (zero pads and zero to one safety pad), time to continence, potency (erection sufficient for sexual activity), EPIC-CP urinary incontinence, sexual function, and overall QOL scores. RESULTS AND LIMITATIONS: Median follow-up for S-RARP versus RS-RARP was 46.3 versus 12.3 mo. RS-RARP versus S-RARP had improved overall continence rates at total follow-up (95.7% vs 85.7%, p = 0.042) and 12-mo follow-up (97.6% vs 81.4%, p = 0.002), and faster return to continence (zero to one safety pad, 44 vs 131 d, p < 0.001). RS-RARP EPIC-CP urinary incontinence and overall QOL scores remained significantly better at 12 mo. There were no differences in overall PSM rates, although RS-RARP had lower rates of nonfocal PSMs. There were no differences in sexual function. In multivariate analysis, RS-RARP was significantly associated with improved 12-mo EPIC-CP urinary incontinence and improved QOL scores, but was not associated with PSM or biochemical recurrence. Limitations include retrospective study design and unequal follow-up; however, significantly better RS-RARP continence at 12 mo is striking despite fewer patients attaining 12-mo follow-up. CONCLUSIONS: RS-RARP significantly improves early and long-term continence without compromising oncologic outcomes and leads to overall improved QOL. PATIENT SUMMARY: Retzius-sparing robot-assisted radical prostatectomy is an emerging technique for robotic radical prostatectomy that improves urinary function and quality of life without compromising cancer control.
引用
- Egan J, Marhamati S, Carvalho FLF, et al. Retzius-sparing Robot-assisted Radical Prostatectomy Leads to Durable Improvement in Urinary Function and Quality of Life Versus Standard Robot-assisted Radical Prostatectomy Without Compromise on Oncologic Efficacy: Single-surgeon Series and Step-by-step Guide. Eur Urol. 2020. PMID: 32536488. doi:10.1016/j.eururo.2020.05.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。